Guardant Health AMEA’s Post

"The road to progress is paved with innovation!" It’s incredible to witness how the field of #molecularprofiling continues to push the boundaries of #precisiononcology, as highlighted at the Molecular Analysis for Precision Oncology Congress (#MAP 2024) in London. With the advancements in whole-genome sequencing (#WGS) and single-cell sequencing, the future of cancer care is bright, particularly when it comes to overcoming #treatmentresistance and identifying new #therapeutictargets. At LINK Medical Solutions, we are proud to support this revolution with our partnership with Tempus, a leader in comprehensive genomic profiling (#CGP). Tempus empowers clinicians with the insights needed to personalise cancer treatment by analysing the unique genetic makeup of each patient’s tumour. As studies at MAP 2024 revealed, the more we understand about the molecular drivers behind cancer, the more targeted—and effective—our therapies can become. For oncologists seeking to stay ahead of the curve, Tempus offers actionable genomic data to support informed treatment decisions, with results that extend far beyond routine sequencing. By leveraging the latest advancements, including #WES (whole exome sequencing) and #WTS (whole transcriptomic sequencing) data, Tempus ensures that no detail is overlooked in the fight against cancer. Exciting times ahead for precision oncology—and we are proud to be part of this journey by making Tempus' transformational CGP technology widely accessible to clinicians and patients. Together, we are improving outcomes and transforming lives.✨ #Tempus #LinkMedicalSolutions #PrecisionOncology #CancerCare #InnovationInOncology #FutureOfHealthcare #GenomicData

🚨 New Research Spotlight 🚨 Another remarkable customer publication in Nature Cancer using 36-plex PhenoCycler (formerly CODEX) data from 401 patients with hepatocellular carcinoma (HCC) unveils a comprehensive spatial map of single-cell phenotypes and multicellular neighborhoods, shedding light on spatial heterogeneity in cancer progression. 🔬 Key Findings: 1. Spatial Niches: Tumor cells, CD4+ and CD8+ T cells, and macrophages cluster into distinct spatial niches, revealing how specific environments drive tumor behavior and progression. 2. Clinical Stratification: Researchers identified three distinct Spatial Phenotypes (SP-HI, SP-LI, and SP-PF), which could stratify clinical outcomes. SP-HI patients may benefit from immune checkpoint blockade (ICB), while SP-PF and SP-LI suggest alternative therapies such as tyrosine kinase inhibitors. 3. VIMhigh Macrophages: An integrated analysis combining PhenoCycler (formerly CODEX), scRNA-seq, and spatial transcriptomics (ST) revealed that VIMhigh macrophages enhance the immunosuppressive function of Treg cells, suggesting a crucial role in HCC progression and immunotherapy response. 🎉 Congratulations to the authors for this significant contribution to advancing liver cancer research and spatial biology! 🔗Read more: https://lnkd.in/gtWSCbiU #NewResearchSpotlight #TheSpatialBiologyCompany #PhenoCycler #HCC #PhenomenalPublications #CancerResearch #SpatialOmics #PrecisionMedicine #Immunotherapy #TumorMicroenvironment #LiverCancer #SingleCell

🔬Breakthrough in 𝐩𝐚𝐧𝐜𝐫𝐞𝐚𝐭𝐢𝐜 𝐜𝐚𝐧𝐜𝐞𝐫 research! A recent study, published in Oncotarget, explores the genetic and therapeutic landscapes of pancreatic adenocarcinomas using 𝐧𝐞𝐱𝐭-𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐬𝐞𝐪𝐮𝐞𝐧𝐜𝐢𝐧𝐠 𝐚𝐧𝐝 𝐦𝐚𝐜𝐡𝐢𝐧𝐞 𝐥𝐞𝐚𝐫𝐧𝐢𝐧𝐠. With PCa responsible for 7% 𝐨𝐟 𝐚𝐥𝐥 𝐜𝐚𝐧𝐜𝐞𝐫 𝐝𝐞𝐚𝐭𝐡𝐬 and known for its low survival rates, personalized treatments are critical. Led by researchers from esteemed institutions, including the 𝐌𝐢𝐧𝐢𝐬𝐭𝐫𝐲 𝐨𝐟 𝐇𝐞𝐚𝐥𝐭𝐡 𝐨𝐟 𝐭𝐡𝐞 𝐑𝐮𝐬𝐬𝐢𝐚𝐧 𝐅𝐞𝐝𝐞𝐫𝐚𝐭𝐢𝐨𝐧 and 𝐏𝐢𝐫𝐨𝐠𝐨𝐯 𝐑𝐮𝐬𝐬𝐢𝐚𝐧 𝐍𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐔𝐧𝐢𝐯𝐞𝐫𝐬𝐢𝐭𝐲, the study aimed to map the mutational landscape of PCa in the Russian population. By applying machine learning to individual exome data, personalized treatment recommendations were generated for each clinical case, offering hope for improved outcomes. 🎉 #PancreaticCancer #NGS #MachineLearning #PersonalizedMedicine Read more here:

🧠💡 Exciting Research Announcement! 💡🧠 Our latest research, funded by the PRIN PNRR project on Glioblastoma multiforme (GBM), is making waves in the field of brain cancer research. GBM, the most tremendous brain tumor, poses significant challenges with its high prevalence and poor survival rates. Despite advancements, treatment options remain limited, underscoring the urgent need for innovative approaches. 🚀 Our manuscript, based on a comprehensive analysis of GBM molecular dynamics and interactions within the tumor microenvironment (TME), unveils potential therapeutic targets and diagnostic biomarkers. By leveraging data from cutting-edge bioinformatic tools, we've identified key protein pathways in astrocytes and myeloid cells that could be harnessed for targeted therapies. 🎯 Moreover, our research highlights the crucial role of extracellular vesicles (EVs) in shaping the microenvironment conducive to cancer progression. This sheds light on their potential utility in early GBM detection through biomarker identification. 🌟 Stay tuned for more updates as we continue our quest to revolutionize GBM treatment and diagnosis! Together, we're making strides towards a brighter future for patients battling this devastating disease. 💪 #GBMResearch #PRINPNRR #BrainCancerAwareness #InnovationInScience #extracellularvesicles #tumormicroenvironment Agata Grazia D'Amico ASSUNTA VIRTUOSO Giuseppa D'Amico Alessandra Maria Vitale Federica Scalia Funded by European Union–Next Generation EU” componente M4C2, investimento 1.1, “Fondo per il Programma Nazionale di Ricerca e Progetti di Rilevante Interesse Nazionale (PRIN)”—CUP: B53D23032960001, Implementation of a patient-derived 3D model of glioblastoma multiforme for the developing of extracellular vesicles-based drug delivery system (EXANDROIDEXtracellular vesicles pAtieNt-DeRived 3d gbm mOdel drug delIvery Developing).

Today at the American Association for Cancer Research (AACR) Annual Meeting, AbbVie will present two studies using ConcertAI’s RWD360™ linked with Caris Life Sciences lab data. One poster session will dive into the comprehensive analysis of 2,659 lung cancer patients. The findings showcase the potential of RWD in identifying unique molecular signatures, analyzing patient treatment patterns, and unlocking personalized medicine. The second study explores the untapped potential of hematoxylin and eosin (H&E) stained histologic sections in providing invaluable oncological insights. Using AI applications employing deep learning (DL), the study developed an unsupervised DL workflow to analyze 1,799 H&E images of lung cancer patients, integrating comprehensive patient-level clinical data and genomics. Don’t miss out on these sessions! Poster 1 | Session 45 Harness the power of real-world-data for oncology target and biomarker research: A case study by applying clinic-genomics data for 2,659 lung cancer patients and beyond Learn more: https://hubs.ly/Q02s6shC0 Poster 2 | Session 36 Integrating real-world histopathological and clinicogenomic data from 1799 lung cancer patients by applying unsupervised deep learning Learn more: https://hubs.ly/Q02s6lRw0 #AACR #RealWorldData #OncologyResearch #LungCancerResearch #DeepLearning #Histopathology

Pan-#Cancer #SingleCell Dissection Reveals Phenotypically Distinct B-Cell Subtypes | Keeping #TAABs on #Tumor-Associated #Atypical #Bcells as a Predictor of #Immunotherapy Success | Breaking Study at Cell Press 👏 | Characterizing the compositional and phenotypic characteristics of tumor-infiltrating B cells (TIBs) is important for advancing our understanding of their role in cancer development. Here*, researchers establish a comprehensive resource of human B cells by integrating single-cell RNA sequencing data of B cells from 649 patients across 19 major cancer types. They demonstrate substantial heterogeneity in their total abundance and subtype composition and observe immunoglobulin G (IgG)-skewness of antibody-secreting cell isotypes. Moreover, they identify stress-response memory B cells and tumor-associated atypical B cells (TAABs), two tumor-enriched subpopulations with prognostic potential, shared in a pan-cancer manner. In particular, TAABs, characterized by a high clonal expansion level and proliferative capacity as well as by close interactions with activated CD4 T cells in tumors, are predictive of immunotherapy response. This integrative resource depicts distinct clinically relevant TIB subsets, laying a foundation for further exploration of functional commonality and diversity of B cells in cancer. *https://lnkd.in/ej4vRBRg Celentyx Ltd #immunooncology www.celentyx.com Professor Nicholas Barnes PhD, FBPhS Omar Qureshi Catherine Brady GRAPHICAL ABSTRACT

🔬Focus on precision oncology: The Future of Cancer Treatment👩⚕️ A look at the world of molecular pathology in precision oncology reveals a groundbreaking shift toward tailored therapies for cancer patients. From the identification of tumor-specific molecular aberrations to the benefits of biomarker-targeted treatment, the possibilities are endless🚀. With the integration of liquid biopsies and the expansion of precision medicine beyond genomics, the challenges of interpreting genomic analyses are being addressed head-on💡. Standardization, education, and access to molecular tumor boards are key to improving clinical interpretation and treatment strategies. Examining studies of next-generation sequencing, liquid biopsies, and targeted therapies in various cancer types sheds light on the potential of multicomic approaches and personalized treatment algorithms. However, barriers such as limited access to targeted agents, high costs, and limitations in clinical trials are challenging the implementation of precision medicine⚠️. The integration of biomarkers, genetic testing and molecular profiling into cancer patient care decision making is a critical step toward better outcomes🎯 #MolecularPathology #PrecisionMedicine #GenomicAnalysis #CancerResearch #NextGenSequencing #TargetedTherapies #PersonalizedMedicine #MolecularProfiling #ClinicalOncology

📊 Have you discovered our case study about how multi-omic data from high quality liver cancer patient samples can drive insights in to precision medicine yet? In this study, tumor and normal tissue samples were taken from a 62-year-old man with hepatocellular carcinoma for multi-omic analysis. The results were published in Discover Oncology from our Global Clinical Network partners led by Prof. Massimiliano Agostini and Prof. Gerry Melino at the Università di Roma Tor Vergata. Genomic, proteomic and transcriptomic analysis revealed a number of biomarkers indicative of resistance to treatment and poor prognosis. The cancer was also highly mutated in a way that is not usually seen in this type of cancer, pointing to a defect in DNA damage repair that could potentially be targeted with drugs such as PARP inhibitors. The findings underline how detailed multi-omic analysis offers the opportunity to deliver more effective, personalized treatment for people with liver cancer. And it highlights the benefits of being part of the Indivumed Global Clinical Network, by getting direct access to curated multi-omics data so patients can benefit from advances in precision medicine. 📄➡️ Read the paper here: https://lnkd.in/euqQTViw #biomarkers #oncology #PrecisionMedicine #Multiomics

BiME® (Bispecific Macrophage Engager) is an innovative immune cell engager platform. BiME@ demonstrates superior safety and potent anti-tumor activities in “cold” tumor models in which T cell engager doesn’t work. Our recent findings provide novel mechanistic insights into how myeloid and T cells can be uniquely modulated by BiME@ and demonstrate the potential and advantage over TCE in future clinical development for solid tumor treatment. We will post the exciting innovation result in upcoming American Association for Cancer Research (AACR) meeting, Dr. Dawei Sun will be on site to share more exciting scientific insights and look forward to the exchanges with you! - Poster Presentation: A Novel Bispecific Antibody Macrophage Engager (BiME) Designed For The Treatment of Solid Tumors - Track: Tumor Biology - Theme: Macrophages, Neutrophils, and NK Cells in Cancer - Session Date and Time: Sunday Apr 7, 2024 1:30 PM - 5:00 PM - Location: Poster Section 7 - Poster Board Number: 25 Learn more about AACR and Elpiscience's poster presentation here: https://lnkd.in/gABWJmt4 #aacr #aacr2024 #biotech #biotechnology #biotechinnovation #bispecific #BiME

💾 Let's recap on groundbreaking advancements in cancer treatment and chemistry, showing how innovation is pushing boundaries in both fields shared by The Babak Lab this week. 💬 If you're interested in how science is driving real change, especially in critical areas like healthcare and elemental research, you’ll want to check this out. It’s a compelling read for anyone curious about the future of science and medicine!